Sanguina Raises $2.8M in Series A Funding to Drive Innovation in Home-Based Testing and Wellness Management

PEACHTREE CORNERS, Ga.–( BUSINESS WIRE )–Sanguina, a leading biotech company focused on providing rapid home-based testing and management solutions, announced today the successful completion of its  $2.8m Series A funding round . Led by  Veritus Holdings , the round saw participation from notable investors, including George Hornig of The Seed Lab and Stephen Ippolito of Veritus Holdings. The funding will be used to accelerate the development and expansion of Sanguina’s innovative blood health management digital and at-home-based platforms.

Sanguina’s mission is to empower individuals by creating a  platform of accessible tools for diagnosing, monitoring, and managing wellness and chronic conditions  from the comfort of their own homes. Founded in 2019 as a spin-off from prestigious institutions such as the Georgia Institute of Technology, Emory University, Children’s Healthcare of Atlanta, and the Centers for Disease Control and Prevention (CDC), Sanguina has quickly made a mark in the biotech sector.

Sanguina logo

George Hornig and Stephen Ippolito of The Seed Lab and Veritus Holdings join Forbes 30u30 inventors and Sanguina co-founders Erika Tyburski and Rob Mannino, PhD, and world-renowned hematologist, Wilbur Lam, MD, PhD, on a Board with knowledge spanning decades in the healthcare, consumer behavior, consumer experience, and financial services industries.

Sanguina’s flagship product, the  AnemoCheck  app, is a digital health platform that estimates hemoglobin levels and aids users in managing anemia. In addition to the app, Sanguina boasts an  FDA-cleared  point-of-care test, which the company plans to expand for home use later this year.  Anemia, characterized by low hemoglobin levels, affects over 1.6bn individuals each year and has always been a marker of both illness and wellness, as it coexists with many chronic diseases and can guide treatment regimens.  In June, two large, independent peer-reviewed published studies featured in the  Annals of Internal Medicine  and  Journal of the American Medical Association (JAMA)  revealed that anemia is a chronic problem for very large categories of Americans, ranging from those taking daily aspirin to women and girls who have iron deficiency from a variety of conditions. Additionally,  clinical hematologists reviewed several studies on anemia  and reveal that chronic health inequity has caused many women and minorities to normalize their anemia.

With advancements in home testing and artificial intelligence, the management of anemia and other chronic conditions is moving towards preventive and personalized medicine. The Series A funding round will enable Sanguina to enhance its existing product suite with artificial intelligence and machine learning models, improving utility, performance, and accessibility. Furthermore, this funding will pave the way for the introduction of new biomarkers and indications, including home-based testing for circulation, dehydration, for management of other chronic diseases.

“We are thrilled to have secured this funding to further our mission of providing accessible tools for managing wellness and chronic conditions,” said Erika Tyburski, Co-founder and CEO of Sanguina. “This investment will enable us to enhance our technology and platforms, bringing us closer to our vision of becoming a leading provider of home-based testing solutions.”

With the successful launch of  anemia   management  through the AnemoCheck app and point-of-care test, Sanguina has  taken a major stride towards  revolutionizing home-based testing and personalized disease management.

About Sanguina, Inc.

Sanguina, Inc.  (Sanguina)  is a leading biotech company focused on advancing accessible digital and at-home health platforms for rapid home-based testing and disease management. Founded in 2019, Sanguina aims to empower individuals by providing innovative solutions for diagnosing, monitoring, and managing wellness and chronic conditions. With a team of experienced scientists, engineers, and healthcare professionals, Sanguina is committed to positively impacting global healthcare. To learn more about Sanguina, please visit  sanguina.com  or on social media through  Instagram ,  Facebook ,  Twitter , or  LinkedIn.

Website:  www.sanguina.com

Who is Sanguina  video

Contacts

Jessica Tackett
Director of Marketing
jessy.tackett@sanguina.com

BIO Statement on the Section 232 Pharmaceutical Proclamation

April 4, 2026
April 2, 2026- WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) , released the following statement on Section 232 Pharmaceutical Proclamation. “A thriving American biotechnology ecosystem is essential to growing the U.S. economy, strengthening national security, and improving the health and well‑being of everyday Americans. While we appreciate the Administration’s recognition of the need for tariff exemptions for certain critical biotech products, the reality is that any tariffs on America’s medicines will raise costs, impede domestic manufacturing, and delay the development of new treatments - all while doing nothing to enhance our national security. “U.S. biotech companies have been eager to expand investments here at home, but tariffs, along with an uncertain policy environment and efforts to force “most‑favored nation” schemes, work directly against that goal. The risks are especially acute for small and mid‑size biotech companies, which develop more than half of all FDA‑approved medicines yet often lack the capital to build dedicated manufacturing facilities as they weather an industry defined by high costs, long development timelines, and significant risk. “The fact is: tariffs divert scarce resources away from research and development, weaken American biotech against China’s rising industry, and ultimately, harm health and economic wellbeing of Americans. “We stand ready to work with the Administration on a long‑term strategy that encourages biotechnology investment, reduces the time, cost, and uncertainty of developing new medicines, expands U.S. biomanufacturing capacity, and ensures American innovation is fairly valued overseas. Tariffs and MFN are not the answer." Source - https://www.bio.org/press-release/bio-statement-section-232-pharmaceutical-proclamation

Georgia Life Sciences Announces 2026 Georgia BioGENEius Challenge Winner

April 1, 2026
Atlanta, GA (April 1, 2026) – Georgia Life Sciences (GLS) is proud to announce that Saisurya Lakkimsetti, a junior at Lakeside High School in Columbia County, has been named the winner of the 2026 Georgia BioGENEius Challenge. The Georgia BioGENEius Challenge took place, as part of the statewide Georgia Science and Engineering Fair (GSEF) at the Classic Center in Athens, Georgia. Forty-seven students from across Georgia competed for this year’s title and cash prize. Jaehyeon Lee, an 11th-grade student from Walton High School, was named runner-up in this year’s competition. The Georgia BioGENEius Challenge recognizes outstanding high school students who are conducting innovative biotechnology research with real-world applications. This year’s top projects, presented in the Global Healthcare Challenge track, demonstrated exceptional scientific rigor and forward-thinking potential in addressing critical healthcare challenges. Saisurya’s research focuses on identifying potential inhibitors for Endocan, a protein known to play a role in glioblastoma tumor growth. Using advanced computational modeling techniques—including AlphaFold and molecular docking tools—she screened thousands of small molecules to identify compounds that may block tumor-promoting signaling pathways. Her work identified several promising candidates that could serve as a foundation for future drug development targeting glioblastoma. Jaehyeon’s project investigates how varying glucose concentrations affect regeneration in planaria, modeling impaired wound healing in diabetic conditions. By testing graded glucose environments and measuring regeneration indicators such as growth and differentiation, Jaehyeon demonstrated that lower glucose levels enhance regeneration while higher levels inhibit healing. The study establishes a model to better understand hyperglycemia’s impact on diabetic wound healing. “The work by these students is a powerful example of the innovation and determination we see in Georgia’s next generation of life sciences leaders,” said Maria Thacker Goethe, President and CEO of Georgia Life Sciences. “The BioGENEius Challenge is critical because it provides students with a platform to apply cutting-edge science to real-world problems, while also strengthening the future workforce that will drive breakthroughs in healthcare, biotechnology, and beyond.” The Georgia BioGENEius Challenge is part of Georgia Life Sciences’ broader commitment to advancing workforce development and fostering innovation across the state’s rapidly growing life sciences ecosystem. Judging the 2026 Georgia BioGENEius Challenge: Ian Biggs; Ralph Cordell, CDC; Alex Harvey, ViaMune; Jamie Graham, Smith Gambrell Russell; and Evan Scullin, LuminiSci.

Georgia Life Science's Feature in Very First Atlanta Edition of Inside Medicine

March 24, 2026
Georgia Life Sciences is thrilled to be featured in the very first Atlanta edition of Inside Medicine . This inaugural issue represents something truly special. Atlanta’s healthcare and life sciences community is driven by innovation, collaboration, and outstanding leadership—and we’re honored to be part of this exciting launch. Also in the issue, GLS's Kennedy Dumas is featured, sharing her journey on how observation and research evolved into a powerful practice of journaling. As the founder of Stationery Black, she creates notebooks designed to showcase, uplift, and inspire people of color. Read the full article here.
MORE POSTS